Form 4: Prothena CEO Granted 520,000 Stock Options

Prothena's President and CEO, Gene G. Kinney, was granted 520,000 stock options with an exercise price of $9.36, vesting over a four-year period.

Summary

• Gene G. Kinney, President and CEO of Prothena Corp Public Ltd Co (PRTA), was granted 520,000 stock options.
• The options have an exercise price of $9.36 per share.
• The transaction date for this grant was March 3, 2026.
• The options will vest as to 25% of the total number of shares on March 3, 2027.
• The remaining options will vest in successive, equal monthly installments of 1/48th of the total number of shares on each monthly anniversary thereafter.
• Vesting is contingent upon Mr. Kinney's continued employment with Prothena.
• The options have an expiration date of March 3, 2036.
• Following this transaction, Mr. Kinney beneficially owns 520,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns the CEO's financial incentives with the company's long-term success, which is generally favorable for shareholders.

Positives

• The grant of 520,000 stock options to the President and CEO aligns executive incentives with long-term shareholder value creation.
• The exercise price of $9.36 suggests a belief in future stock price appreciation above this level for the options to be valuable.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates a long-term commitment from the CEO and aligns his financial interests with the company's sustained performance and growth over this period.

Industry Context

StockSavvy.ai notes that granting stock options with multi-year vesting schedules is a common practice in the biotechnology and pharmaceutical industries to incentivize executive retention and align leadership's interests with long-term company performance and shareholder returns. This type of compensation structure is particularly prevalent in sectors where product development cycles are extensive and require sustained strategic oversight.

Comparison to Industry Standards

• The grant of 520,000 stock options to a CEO of a publicly traded biotech company like Prothena is within the typical range for executive compensation packages, especially for companies in development stages or with significant pipeline potential.
• The four-year vesting schedule, with a one-year cliff and monthly vesting thereafter, is a standard industry practice designed to promote long-term executive retention and performance, comparable to structures seen at companies such as Biogen or Regeneron for similar executive roles.

Stakeholder Impact

• Shareholders: The option grant aligns the CEO's interests with shareholders, potentially leading to more focused efforts on increasing stock value.
• Employees: May signal stability in leadership and a long-term vision for the company.

Next Steps

• The stock options will begin to vest on March 3, 2027, with subsequent monthly vesting installments.

Key Dates

Keywords

Prothena, PRTA, Stock Options, Executive Compensation, Insider Transaction, Gene G. Kinney, CEO, Vesting Schedule